Latest period
$686M
YoY change
-1.8%
5Y CAGR
+9.8%
Peak year (FY2024)
$699M
Latest annual
$686M
Stock-Based Compensation history chart for Vertex Pharmaceuticals (VRTX) from 2016 to 2025
Latest: $686M
Stock-Based Compensation growth chart for Vertex Pharmaceuticals (VRTX) from 2016 to 2025
Latest: -1.8%
Stock-Based Compensation history table for Vertex Pharmaceuticals (VRTX) from 1991 to 2025
| FY2025 | $686M | -1.8% | -$12.6M | ||
| FY2024 | $699M | +20.2% | +$117M | ||
| FY2023 | $581M | +18.3% | +$89.9M | ||
| FY2022 | $491M | +11.3% | +$49.9M | ||
| FY2021 | $441M | +2.8% | +$11.9M | ||
| FY2020 | $430M | +19.1% | +$69M | ||
| FY2019 | $360M | +10.9% | +$35.4M | ||
| FY2018 | $325M | +11.8% | +$34.3M | ||
| FY2017 | $291M | +22.3% | +$53M | ||
| FY2016 | $238M | +2.9% | +$6.68M | ||
| FY2015 | $231M | +30.1% | +$53.5M | ||
| FY2014 | $178M | +39.5% | +$50.2M | ||
| FY2013 | $127M | +11.4% | +$13M | ||
| FY2012 | $114M | -9.8% | -$12.5M | ||
| FY2011 | $127M | +29.8% | +$29.1M | ||
| FY2010 | $97.7M | +12.6% | +$11M | ||
| FY2009 | $86.7M | +37.6% | +$23.7M | ||
| FY2008 | $63M | +6.1% | +$3.61M | ||
| FY2007 | $59.4M | +51.8% | +$20.3M | ||
| FY2006 | $39.1M | +419.7% | +$31.6M | ||
| FY2005 | $7.53M | +80.8% | +$3.37M | ||
| FY2004 | $4.17M | +32.4% | +$1.02M | ||
| FY2003 | $3.15M | +109.6% | +$1.65M | ||
| FY2002 | $1.5M | — | +$1.5M | ||
| FY2001 | $0.00 | — | $0.00 | ||
| FY2000 | $0.00 | — | $0.00 | ||
| FY1999 | $0.00 | — | $0.00 | ||
| FY1998 | $0.00 | — | $0.00 | ||
| FY1997 | $0.00 | — | $0.00 | ||
| FY1996 | $0.00 | — | $0.00 | ||
| FY1995 | $0.00 | — | $0.00 | ||
| FY1994 | $0.00 | — | $0.00 | ||
| FY1993 | $0.00 | — | $0.00 | ||
| FY1992 | $0.00 | — | $0.00 | ||
| FY1991 | $0.00 | — | — |
- FY2025$686M-1.8%
- FY2024$699M+20.2%
- FY2023$581M+18.3%
- FY2022$491M+11.3%
- FY2021$441M+2.8%
- FY2020$430M+19.1%
- FY2019$360M+10.9%
- FY2018$325M+11.8%
- FY2017$291M+22.3%
- FY2016$238M+2.9%
- FY2015$231M+30.1%
- FY2014$178M+39.5%
- FY2013$127M+11.4%
- FY2012$114M-9.8%
- FY2011$127M+29.8%
- FY2010$97.7M+12.6%
- FY2009$86.7M+37.6%
- FY2008$63M+6.1%
- FY2007$59.4M+51.8%
- FY2006$39.1M+419.7%
- FY2005$7.53M+80.8%
- FY2004$4.17M+32.4%
- FY2003$3.15M+109.6%
- FY2002$1.5M—
- FY2001$0.00—
- FY2000$0.00—
- FY1999$0.00—
- FY1998$0.00—
- FY1997$0.00—
- FY1996$0.00—
- FY1995$0.00—
- FY1994$0.00—
- FY1993$0.00—
- FY1992$0.00—
- FY1991$0.00—
Stock-Based Compensation values are taken from Vertex Pharmaceuticals's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Stock-Based Compensation at Vertex Pharmaceuticals (VRTX)
Stock-Based Compensation for Vertex Pharmaceuticals (VRTX): headline value $686M · YoY -1.8%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Vertex Pharmaceuticals (VRTX) most recent annual stock-based compensation stands at $686M (2025) – edged down 1.8% year-over-year.
Vertex Pharmaceuticals stock-based compensation has grown on net over the period, with a +9.8% compound annual growth rate over 2020–2025 (5 years).
Across the available history, stock-based compensation reached its high of $699M in 2024 and its low of $0.00 in 1991.
Vertex Pharmaceuticals Stock-Based Compensation by Year
Vertex Pharmaceuticals Stock-Based Compensation 2025: $686M
Vertex Pharmaceuticals stock-based compensation in 2025 was $686M, edged down 1.8% below 2024.
Vertex Pharmaceuticals Stock-Based Compensation 2024: $699M
2024's stock-based compensation for Vertex Pharmaceuticals came in at $699M, grew 20.2% from 2023. This figure represents the highest annual value in the available history.
Vertex Pharmaceuticals Stock-Based Compensation 2023: $581M
Vertex Pharmaceuticals posted stock-based compensation of $581M in 2023, grew 18.3% from 2022.
Vertex Pharmaceuticals Stock-Based Compensation 2022: $491M
In 2022, Vertex Pharmaceuticals reported stock-based compensation of $491M, grew 11.3% from 2021.
Vertex Pharmaceuticals Stock-Based Compensation 2021: $441M
Vertex Pharmaceuticals stock-based compensation in 2021 was $441M.
See more financial history for Vertex Pharmaceuticals (VRTX).
Sector peers by Stock-Based Compensation
Healthcare peers of Vertex Pharmaceuticals (VRTX), ranked by their latest stock-based compensation
| $1.35B | |
| $971M | |
| $955M | |
| $626M | |
| $494M | |
| $310M | |
| $0.00 | |
| $0.00 |
- $1.35B
- $955M
- $626M
- $494M
- $0.00
- $0.00
Frequently asked questions
Vertex Pharmaceuticals (VRTX) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.